Onco Actu du 15 mai 2020

	2.5 ETIOLOGIE - GÉNOME
Danish Researchers Find New Breast Cancer Gene in Young People [University of Copenhagen] The RBBP8 gene which does the coding for the CtIP protein, has not previously been associated with the development of hereditary breast cancer. In the new study, just published in The Journal of Clinical Investigation, it is the conclusion that these are rare variants and mutations.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
Mapping how evolutionary forces affect cancer growth could help doctors choose biopsies [Institute of Cancer Research] The model, which shows how cancer cells with particular mutations can spread through tumours, could more accurately reflect the genetic picture across whole tumours.
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
Moffitt Researchers Develop Model to Predict Prostate Cancer Aggressiveness [Moffitt Cancer Center] “Our results demonstrate that traditional metrics like the Gleason score, which are often tumor-cell centric, could be improved with ecological metrics.”
	4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
Bayer and ArcherDX to develop next-generation sequencing (NGS)-based companion diagnostic (CDx) for precision oncology treatment Vitrakvi™ [Bayer] Collaboration focus on development of a companion diagnostic (CDx) for Vitrakvi™ (larotrectinib), the first and only TRK inhibitor approved in Europe for adult and pediatric patients with TRK fusion cancer across all solid tumors.
	5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline [Xconomy] The assets acquired from Northern Biologics in the deal, announced Thursday, are designed to target two aspects of what’s known as the tumor microenvironment: stroma, or connective tissue made up of different cell types, and myeloid cells.
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio [Boehringer Ingelheim] These new programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology, with leading assets and robust capabilities in cancer vaccines, oncolytic viruses, T-cell engagers and myeloid cell modulators.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Moffitt Cancer Center Study Suggests More Could Benefit from CAR T-Cell Therapy [Moffitt Cancer Center] “Durable response rates were encouraging even in patients with significant comorbidities, suggesting that patients need not meet ZUMA-1 eligibility criteria to benefit from axicabtagene ciloleucel.”
	5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
Combination of chemo and immunotherapy is shown to work against metastatic bladder cancer [EurekAlert!] he trial also showed that immunotherapy alone may be an option for a subset of patients with metastatic bladder cancer if their tumor expresses a high level of a protein called PD-L1 according to the study, published in The Lancet in May.
	5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
J&J-backed CAR-T biotech Legend guns for $100M IPO but sees CRS death in early trial [Fierce Biotech] For the phase 1b portion of the CARTITUDE-1 trial, it revealed that as of April 29, 2020, cytokine release syndrome (CRS), a common but sometimes deadly side effect of cell therapies, was reported in 93% of patients.
BCMA rival to bluebird, Bristol Myers files for $100M IPO as the frontrunners stumble in a race to the finish line [EndPoints] The company is China’s Legend Biotech, which has taken an office in New Jersey as the research team with J&J steers LCAR-B38M/JNJ-4528 through a registration program after scoring some jaw-dropping data for their cell therapy in multiple myeloma.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma [Takeda] Approval is Based on Results of Phase 3 ECHELON-2 Trial, Which Demonstrated Treatment with ADCETRIS Plus CHP (cyclophosphamide, doxorubicin, prednisone) Resulted in Significant Improvement in Progression-Free Survival Compared with a Standard of Care.
	5.4 TRAITEMENTS - ECONOMIE
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer [Nice] It is recommended only if the company provides lorlatinib according to the commercial arrangement.
	5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
Foundation Medicine and Collaborators to Share New Data During the ASCO20 Virtual Scientific Program Showcasing the Importance of Comprehensive Genomic Profiling (CGP) in Informing Advanced Cancer Clinical Decision-Making [Foundation Medicine] The data highlight insights into the utility of liquid biopsy CGP testing to help inform treatment selection across a variety of advanced cancers and the predictive role of tumor mutational burden (TMB) as a genomic signature to optimize precision medicine approaches.
Cancer biotech stocks shift on glimpse of ASCO data [Biopharma Dive] Allogene Therapeutics appeared a clear winner, with shares in the biotech rising by nearly 30% on early signs its "off-the-shelf" cancer cell therapy could be effective in treating lymphoma. The preliminary data seemed to also help Cellectis.
Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline [Takeda] 11 Takeda Oncology-Sponsored Abstracts Accepted for Presentation at the 2020 American Society of Clinical Oncology (ASCO) Meeting and 22 Abstracts Accepted for Presentation at the 2020 Congress of the European Hematology Association (EHA).
	5.5.10 ASCO (HÉMATO)
Janssen’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma [Janssen] Longer-term follow-up data from Phase 1b/2 CARTITUDE-1 study demonstrate 100% overall response rate, 86% stringent complete response rate at a median of 11.5 months and 86% progression-free survival at 9 months.
	5.5.3 ASCO (PROSTATE)
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer [Janssen] Final analysis of the Phase 3 SPARTAN study presented during ASCO Virtual Scientific Program suggests 14-month improvement in median overall survival.
	5.5.4.4 ASCO (IMMUNOTHÉRAPIES-POUMON)
ASCO: Roche's closely watched TIGIT combo shows 2 checkpoint inhibitors could be better than one [Fierce Biotech] Moving forward, Genentech already has two phase 3 studies of tiragolumab under way.
Roche unveils first data for new type of cancer immunotherapy [Biopharma Dive] Roche executives have talked up the drug's potential at recent events, raising expectations that it, along with other drugs that work similarly, could offer a path to amplify the tumor-killing effects of immunotherapies like Tecentriq.
	5.5.9 ASCO (AUTRES ORGANES)
Trial E3311 validates a less intense treatment for HPV+ throat cancer [ECOG-ACRIN] Randomized phase 2 trial E3311 shows transoral robotic surgery followed by low-dose radiation alone led to very good outcomes, similar to surgery with standard-dose radiation, preserving patients’ throat function and potentially sparing them unnecessary short- and long-term toxicities.